The landmark STICH trial found that surgical revascularization compared to medical therapy alone improved survival in patients with heart failure (HF) of ischaemic aetiology and an ejection fraction (EF) ≤ 35%. However, the interaction between the burden of medical co-morbidities and the benefit from surgical revascularization has not been previously described in patients with ischaemic cardiomyopathy. ..................................................................................................................................................................... 
Introduction
Heart failure (HF) is a public health problem of pandemic proportions with an estimated 38 million patients worldwide.
1 -3 Cardiac and non-cardiac co-morbidities are highly prevalent in HF and many coexisting medical conditions have been independently associated with increased risk of morbidity and mortality. 4, 5 The Charlson co-morbidity index (CCI) is a convenient bedside tool that allows physicians to assess a patient's burden of common cardiac and non-cardiac conditions and estimate the corresponding 10-year survival. 6, 7 The Surgical Treatment for Ischemic Heart Failure (STICH) trial (ClinicalTrials.gov Identifier: NCT00023595) 8 -11 provides a unique opportunity to systematically describe the burden of cardiac and non-cardiac conditions (i.e. defined by CCI) as well as the impact of severity of co-morbid illness on the relative efficacy and safety of medical therapy alone (MED) vs. medical therapy plus coronary artery bypass grafting (MED/CABG) in patients with ischaemic cardiomyopathy and severe left ventricular (LV) dysfunction. Specifically, the objectives of this work are (i) to describe the level of co-morbidity using the CCI, (ii) to study the association between the burden of co-morbid conditions and survival, and (iii) to evaluate the efficacy of MED vs. MED/CABG based on severity of co-morbidity in HF patients of ischaemic aetiology with an ejection fraction (EF) ≤ 35%.
Methods

Overview
The study design 8 and primary results 9 -11 of the STICH trial have been previously reported. Briefly, STICH was an international, multicentre, randomized, active-controlled trial designed to assess the relative efficacy of three possible therapeutic options: MED, MED/CABG, or MED/CABG and surgical ventricular reconstruction. The present analysis includes the 1212 patients enrolled in the hypothesis 1 component of the trial (i.e. MED vs. MED/CABG) at 99 centres in 22 countries between 24 July 2002 and 5 May 2007. Patients ≥ 18 years of age with coronary artery disease (CAD) that was amenable to CABG and an EF ≤ 35% within 3 months of trial entry were eligible for enrolment. Patients with a > 50% left main coronary artery stenosis, Canadian Cardiovascular Society (CCS) grade III or IV angina (i.e. markedly limiting ordinary activity), a non-cardiac illness imposing substantial operative mortality or with a limited life expectancy of < 3 years, or conditions/circumstances limiting treatment adherence were excluded from participation.
Eligible participants were randomly assigned 1:1 to receive MED was responsible for managing background guideline-directed medical therapy for CAD and HF. Adherence to guideline recommendations was emphasized and monitored by a medical therapy committee. Cardiac surgery was performed by surgeons who were required to provide data on a minimum of 25 patients with an EF ≤ 40% in whom they had performed CABG with an operative mortality ≤ 5%. CABG was performed within 14 days of enrolment. All patients were asked to return for follow-up visits at the time of discharge or at 30 days, every 4 months for the first year, and every 6 months thereafter.
Charlson co-morbidity index
The development and validation of the CCI has been previously described. 6, 7 Briefly, the CCI accounts for 16 medical co-morbidities and assigns each condition 1, 2, 3, or 6 points depending on the associated mortality risk. A modified CCI score (i.e. based on the availability of data and study definitions) was computed for each patient enrolled in the STICH trial by summing the weighted points for all co-morbid conditions (online supplementary Table S1 ). A combined age-co-morbidity score was subsequently calculated by adding 1 point for each decade of life over 40 years of age to account for the risk of co-morbid death attributable to age. For example, a 60-year-old patient with HF and a prior myocardial infarction would have a combined age-co-morbidity score (hereafter referred to simply as the CCI) of 4 (i.e. HF = 1 point, myocardial infarction = 1 point, and age of 60 years = 2 points).
The predicted 10-year mortality based on the CCI was calculated as follows: X = e 0.9(CCI) Mortality = 1-0.983
X
Outcomes
The primary endpoint was all-cause mortality. Secondary endpoints included cardiovascular (CV) mortality and the composite of all-cause mortality and CV hospitalizations. Blinding was not pursued due to the nature of the surgical intervention, mode of death and CV hospitalizations for each patient were adjudicated by an independent clinical events committee who were unaware of treatment assignment.
Statistical analysis
All categorical data were reported as a count (percentage) and continuous data as mean (standard deviation) and/or median (25th, 75th percentiles). Patients were divided into mild/moderate (defined as CCI 1-4) and severe (defined as CCI ≥ 5) co-morbid illness. Baseline clinical characteristics including demographics, medical history, medication use, laboratory values, quality of life, and exercise testing were compared between groups. Comparisons for continuous variables were based on the Wilcoxon rank-sum test, while categorical variables were assessed using Pearson's chi-square test or Fisher's exact test as appropriate. Ten-year mortality was calculated in the CCI severity groups using the Kaplan-Meier method. The Kaplan-Meier estimates for each CCI score were plotted with 95% confidence intervals (CIs) in a figure that included the predicted probability of mortality using the previously published CCI equation. 6, 7 Cox proportional hazards regression models were used to evaluate the association between CCI as a categorical variable (mild/moderate = CCI 1-4 vs. severe = CCI ≥ 5) as well as continuous variable (calculated as the risk per additional CCI point) and outcomes. Multivariable Cox models were adjusted for the following baseline covariates: sex, race, region, blood pressure, heart rate, CCS angina class, New York Heart Association (NYHA) class, atrial fibrillation/flutter, hyperlipidaemia, hypertension, prior CABG, prior percutaneous coronary intervention, number of diseased vessels, left main stenosis, proximal left anterior descending stenosis, left ventricular EF, left ventricular end-systolic volume index (LVESVI), moderate or severe mitral regurgitation, haemoglobin, sodium, and estimated glomerular filtration rate as previously identified as being associated with clinical outcomes. 12 The predicted probabilities (95% CI) for 10-year mortality were estimated from an unadjusted Cox model that included CCI (as a continuous covariate). The interaction between severity of co-morbidity as a categorical (mild/moderate = CCI 1-4 vs. severe = CCI ≥ 5) and continuous variable and randomized treatment (CABG/MED vs. MED) with respect to all-cause mortality was assessed with adjusted Cox models that included the CCI severity-by-treatment interaction. Relationships were displayed with Kaplan-Meier plots stratified by treatment separately in the mild/moderate and severe co-morbidity groups along with unadjusted hazard ratios (HR, 95% CI) and interaction P-value, Kaplan-Meier 10-year rates, number of events, and forest plot and spline curves stratified by treatment showing co-morbidity level as a continuous variable with 95% CI and interaction P-value.
P-values < 0.05 from two-sided tests were considered statistically significant. Adjustments were not made for multiple comparisons. All analyses were performed using SAS 9.4 (SAS Institute Inc., Cary, NC, USA).
Results
Study population
A total of 1212 patients with CAD that was amenable to CABG and an EF ≤ 35% were included in the present analysis ( Table 1) . Study participants were a median of 60 (54, 67) years old and 88% were male. The median EF for the study population was 28% (22%, 34%). The median CCI score was 5 (4, 7) with a minimum of 1 and a maximum of 12. A total of 349 patients (29%) had a mild/moderate CCI score and 863 patients (71%) had a severe CCI score at baseline. At the time of randomization, 95% of patients reported no angina or CCS I/II angina and approximately 85% of patients reported NYHA functional class II/III symptoms. Patients were well-treated with guideline-directed medical therapy for CAD and HF at baseline.
Patient characteristics by co-morbidity level
Patients with severe CCI score were more likely to self-identify as white and had greater functional limitations based on 6-min walk . 
Co-morbidity severity and clinical outcomes
The 10-year mortality in the STICH population ranged from approximately 25% for patients with a CCI score of 1 and approached 100% for patients with a CCI score of 12 ( Figure 1A ). A total of 161 patients (50%) with a mild/moderate CCI score and 579 patients (69%) with a severe CCI score died over a median follow-up of 9.8 years ( Table 2 ). In addition, the composite of all-cause mortality or CV hospitalization was reached in 254 patients (79%) with a mild/moderate CCI score and in 731 patients (87%) with a severe CCI score over the same timeframe. The predicted 10-year mortality based on the CCI and the actual mortality for the STICH cohort are shown in Figure 1B . In general, the estimated 10-year mortality derived from the CCI tended to underestimate the risk of death for patients with a CCI score < 4 and overestimate the risk of death for patients with a CCI score > 4.
Patients with a severe CCI score were at higher risk for all-cause mortality (HR 1.44, 95% CI 1.19-1.74; P <0.001), CV mortality (HR 1.35, 95% CI 1.09-1.68; P = 0.006), and all-cause mortality or CV hospitalization (HR 1.22, 95% CI 1.04-1.43; P = 0.012). The incremental risk of an adverse event per 1-point increase in CCI score was comparable for all-cause mortality (HR 1.12, 95% CI 1.06-1.18; P <0.001), CV mortality (HR 1.11, 95% CI 1.04-1.18; P < 0.001), and all-cause mortality or CV hospitalization (HR 1.07, 95% CI 1.02-1.12; P = 0.003).
Efficacy of surgical revascularization by co-morbidity level
There was no interaction between CCI score (mild/moderate vs. severe) and treatment effect (MED vs. MED/CABG) with respect to all-cause (Figure 2A ) or CV mortality ( Figure 2B ) at 10 years in the intention-to-treat population. In contrast, although patients randomized to MED/CABG were less likely to reach the composite of all-cause mortality or CV hospitalization irrespective of CCI score, patients with a mild/moderate CCI score derived a more robust benefit from surgical revascularization over the same timeframe ( Figure 2C) . A sensitivity analysis did not reveal an interaction between CCI score and treatment effect with respect to all-cause mortality, CV mortality, or the composite of all-cause mortality or CV hospitalization in the as-treated cohort (online supplementary Figure S1 ). Figure 3 shows spline curves for all-cause mortality, CV mortality, and the composite of all-cause mortality or CV hospitalization at 1, 5, and 10 years for the intention-to-treat population. In general, the results of the interaction analyses with CCI score as a continuous variable were consistent with those observed with CCI score as a categorical variable (mild/moderate vs. severe). For example, there was no interaction between CCI score as a continuous variable and treatment effect (MED vs. MED/CABG) with respect to all-cause (P = 0.115) or CV mortality (P = 0.275). Similarly, patients with a CCI score in the mild/moderate range (i.e. 1-4) undergoing surgical revascularization experienced an earlier and more marked improvement in the composite of all-cause mortality or CV hospitalization compared to patients receiving medical therapy alone (P = 0.021).
Discussion
This study found that more than 70% of the patients enrolled in the STICH trial had a severe burden of medical co-morbidities at baseline. Patients with a severe level of co-morbidity had greater functional limitations and impairments in health-related quality of life. In addition, these patients experienced an exceptionally poor prognosis with mortality approaching 70% at 10 years. After adjusting for potential confounders, all-cause mortality was almost 45% higher for patients with a severe CCI score and the incremental risk of death per 1-point increase in CCI score was in excess of 10%. However, patients with ischaemic cardiomyopathy and a severe burden of medical co-morbidities derived a comparable survival benefit from surgical revascularization over the duration of follow-up. It is notable that more than 70% of study participants had a CCI score in the severe range. underestimates the real-world burden of medical co-morbidities in patients with ischaemic cardiomyopathy and severe LV systolic dysfunction as the STICH protocol excluded participants with a non-cardiac illness imposing substantial operative mortality or with a limited life expectancy. 8 There is a growing appreciation of the clinical impact of multimorbidity on the 'patient journey' in HF. 4 This assertion is supported by the fact that patients with a severe CCI score had worse functional capacity (6-min walk test) and health-related quality of life (KCCQ). These differences were not only statistically significant but also consistent with the generally accepted minimal clinically important difference for these assessments. 13, 14 Interestingly, despite differences in age and co-morbidity profile between patients with mild/moderate and severe CCI scores, there was very little difference in underlying cardiac substrate including coronary anatomy, echocardiographic parameters of remodelling, and symptom status (CCS angina and/or NYHA functional class). In addition, patients with a severe CCI score were equally likely to be treated with evidence-based medications for CAD and HF despite the fact that certain non-cardiac co-morbidities may lead to real or perceived barriers to optimal implementation of guideline-directed medical therapies.
15,16
The CCI was initially developed as a method for quantifying the degree of co-morbidity and assessing prognosis in longitudinal cohort studies. 6, 7 Although a reliable and accurate research tool, there is a more limited experience with the CCI in a HF population and its clinical utility is not well-established. Of note, this study found a relatively linear relationship between CCI score and all-cause mortality at 10 years with the incremental risk of death and estimated 12% per 1-point increase in CCI score independent of traditional prognostic indicators. In addition, since the CCI incorporates age and cardiac and non-cardiac co-morbidities, the risk of CV and non-CV mortality tended to rise proportionally with increasing CCI score and it was found to be equally useful when estimating all-cause and CV-specific mortality in this patient population. Thus, the CCI may supplement clinical judgment and play a meaningful role when discussing life expectancy and prognosis with HF patients. However, it should be noted that the CCI was originally developed in a relatively low-risk cohort. As a result, the previously published regression equation did not perform well in the high-risk STICH population and tended to underestimate the risk of death in patients with a low/moderate CCI score and overestimate the risk of death in patients with a severe CCI score. This finding suggests that additional research is required to prospectively validate the prognostic potential of the CCI in patients with HF in order to provide reliable and accurate estimates of survival based on co-morbidity burden. More importantly, in an era of personalized medicine it is relevant to consider the impact of severity of co-morbidity on the relative efficacy and safety of surgical revascularization in patients . Adjusted for sex, race, region, blood pressure, heart rate, Canadian Cardiovascular Society angina class, New York Heart Association class, atrial fibrillation/flutter, hyperlipidaemia, hypertension, prior coronary artery bypass grafting, prior percutaneous coronary intervention, number of diseased vessels, left main stenosis, proximal left anterior descending stenosis, left ventricular ejection fraction, and left ventricular end-systolic volume index, moderate or severe mitral regurgitation, haemoglobin, sodium, estimated glomerular filtration rate, and randomized treatment. with ischaemic cardiomyopathy and severe LV systolic dysfunction. In general, patients undergoing major cardiovascular surgery are exposed to perioperative/postoperative complications with the expectation that by correcting the underlying cardiac pathology this upfront risk will eventually be offset by a long-term reduction in CV morbidity and mortality. This generalization is consistent with the primary results of the STICH trial, which demonstrated that although mortality was initially higher in patients randomized to surgical revascularization, the survival curves crossed over after the 2-year mark and a statistically significant benefit emerged over a median follow-up of 9.8 years. 9 -11 In contrast, this study found that among patients with a mild/moderate CCI, the Kaplan-Meier plots for all-cause mortality for MED vs. MED/CABG did not exhibit this crossover phenomenon but rather paralleled one another initially before demonstrating a potentially earlier and more pronounced survival benefit with surgical revascularization. In addition, although patients randomized to MED/CABG were at lower risk for the . . composite of all-cause mortality or CV hospitalization irrespective of CCI score, patients with a mild/moderate CCI score derived a more robust benefit from surgical revascularization driven by a reduction in CV hospitalizations. Thus, among patients with HF of ischaemic aetiology who are young and relatively free of co-morbid conditions, surgical revascularization poses minimal upfront risk and these patients experience an early and dramatic improvement in all-cause and CV-specific morbidity and mortality compared to medical therapy alone. However, it cannot be overemphasized that this study found no interaction between co-morbidity level and all-cause and CV mortality at 10 years suggesting that elderly patients with a severe burden of medical co-morbidities should not be denied surgical revascularization based on these factors alone. The decision to refer a patient with ischaemic cardiomyopathy and severe LV systolic dysfunction for CABG should be individualized and take into account age, parameters of remodelling (i.e. LVEF and LVESVI), 19 and functional capacity. 20 There are several limitations of the data that should be acknowledged. First, patients with a non-cardiac illness imposing substantial operative mortality or with a limited life expectancy were excluded from enrolment potentially restricting the generalizability of the data to an otherwise unselected real-world population of patients with ischaemic cardiomyopathy and severe LV systolic dysfunction. Second, the STICH protocol did not require reporting of several medical co-morbidities (i.e. liver disease and acute immunodeficiency syndrome) included in the CCI. Third, although more than 70% of patients had a severe level of co-morbidity, there were very few patients with a CCI > 8 (i.e. ∼6%) and the possibility that there was heterogeneity in treatment effect (i.e. MED vs. MED/CABG) cannot be excluded for this subset of the population. interaction between co-morbidity severity and treatment effect. 21 However, a sensitivity analysis was performed and found no interaction between CCI severity and treatment effect in the as-treated cohort. Finally, due to the nature of surgical revascularization, physicians and patients were necessarily unblinded to treatment assignment although outcomes were adjudicated by a blinded and independent clinical events committee.
Conclusion
More than 70% of patients with ischaemic cardiomyopathy and severe LV systolic dysfunction had a severe burden of medical co-morbidities. Multimorbidity was associated with greater functional limitations and impairments in health-related quality of life and decreased survival. There was not a differential response to MED vs. MED/CABG with respect to all-cause and CV-specific mortality based on severity of co-morbidity among patients with ischaemic cardiomyopathy and severe LV systolic dysfunction. Additional research is required to identify patient and procedural factors that may define patient groups who may derive a more robust or more limited response to surgical revascularization compared to medical therapy alone.
Supplementary Information
Additional supporting information may be found online in the Supporting Information section at the end of the article. Table S1 . Clinical variables and study definitions used to calculate modified Charlson co-morbidity index. Figure S1 . Kaplan-Meier curves for treatment effect (i.e. MED vs. MED/CABG) within Charlson co-morbidity index category (i.e. mild/moderate vs. severe) for (A) all-cause mortality, (B) cardiovascular mortality, and (C) all-cause mortality or cardiovascular hospitalization for the as-treated cohort.
Funding
